Thermo Fisher Scientific (NYSE:TMO) CEO Sells $200,200.00 in Stock

Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Marc Casper sold 400 shares of the business’s stock in a transaction on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares in the company, valued at approximately $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Thermo Fisher Scientific Stock Down 0.8%

TMO opened at $483.80 on Wednesday. The business’s fifty day moving average is $463.59 and its two-hundred day moving average is $452.20. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company has a market cap of $182.69 billion, a price-to-earnings ratio of 27.98, a PEG ratio of 2.60 and a beta of 0.75. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the prior year, the business earned $5.37 earnings per share. The business’s revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.95%.

Institutional Investors Weigh In On Thermo Fisher Scientific

A number of hedge funds have recently bought and sold shares of the business. NWF Advisory Services Inc. acquired a new stake in Thermo Fisher Scientific during the 2nd quarter valued at approximately $377,000. Reynders McVeigh Capital Management LLC grew its stake in Thermo Fisher Scientific by 0.5% during the 2nd quarter. Reynders McVeigh Capital Management LLC now owns 9,710 shares of the medical research company’s stock valued at $3,937,000 after purchasing an additional 45 shares in the last quarter. SevenBridge Financial Group LLC grew its stake in Thermo Fisher Scientific by 38.3% during the 2nd quarter. SevenBridge Financial Group LLC now owns 4,955 shares of the medical research company’s stock valued at $2,009,000 after purchasing an additional 1,371 shares in the last quarter. Osaic Holdings Inc. grew its stake in Thermo Fisher Scientific by 35.7% during the 2nd quarter. Osaic Holdings Inc. now owns 67,715 shares of the medical research company’s stock valued at $28,572,000 after purchasing an additional 17,806 shares in the last quarter. Finally, American Trust lifted its holdings in Thermo Fisher Scientific by 1.7% during the 2nd quarter. American Trust now owns 5,663 shares of the medical research company’s stock worth $2,296,000 after buying an additional 93 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on TMO. Scotiabank upgraded Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price objective on the stock in a research report on Friday, July 11th. Hsbc Global Res downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. HSBC restated a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. Finally, William Blair began coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an “outperform” rating for the company. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $589.38.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.